Contact Us

Amblyotech Acquires Worldwide Rights to a Patented Treatment for Amblyopia from McGill University

Clinical trials indicate the smartphone/tablet application has positive treatment results with pediatric and adult amblyopia patients.

Amblyopia effects 3% of children internationally.

    ATLANTA, GA, October 23, 2013 /24-7PressRelease/ -- Amblyotech, LLC. (Atlanta, GA) and McGill University (Montreal, Canada) are pleased to announce the signing of a license agreement for the world-wide rights to an electronic application for the treatment of amblyopia. Invented by Dr. Robert Hess, a Professor at McGill University and Director of the McGill Vision Research Unit, this treatment is a breakthrough for individuals who suffer from this ocular condition.

"This technology is a patented electronic application that, when used with a smartphone or tablet, dramatically improves the visual acuity of individuals who suffer with amblyopia, also known as lazy eye. Amblyopia affects up to 3% of children internationally and, if unsuccessfully treated, is a leading cause of blindness in adults. Currently these patients have few treatment options. We are pleased to partner with McGill University to bring this technology to market," stated Joseph Koziak, CEO of Amblyotech.

"McGill University has a proud history of innovation and product development in numerous fields, especially the life sciences," stated Dr. Rose Goldstein, McGill's Vice-Principal (Research and International Relations). "It is our pleasure to announce our partnership with Joseph Koziak, Robert Derricotte, and Amblyotech for the development of the amblyopia technology and future opportunities."

"Amblyotech, LLC. will be actively commercializing this technology world-wide, with clinical trials here in Atlanta, Georgia, and throughout the U.S., starting in early 2014," stated Robert Derricotte, COO of Amblyotech, LLC.

About Amblyotech LLC.

Amblyotech LLC was founded by Joseph Koziak and Robert Derricotte to develop and commercialize novel ocular treatments using applications designed for smartphones and tablet platforms. The company plans on building a platform of ocular technologies which are clinically proven to improve visual acuity and quality of life.

About McGill University

Founded in Montreal, Quebec, in 1821, McGill is a leading Canadian post-secondary institution. It has two campuses, 11 faculties, 11 professional schools, 300 programs of study and some 39,000 students, including 9,300 graduate students. McGill attracts students from over 150 countries around the world, with more than 8,200 international students making up 20 per cent of the student body.

For further information contact:

Joseph Koziak, CEO
Amblyotech, LLC.
koziak@amblyotech.com
Ph. 770 366 6229
www.amblyotech.com

Derrick Wong
McGill University
derrick.wong@mcgill.ca
Ph. 514 398 5858


# # #



Comment on this story...

Share This Story


Email this Story

Contact Information


Joseph Koziak
Amblyotech, LLC

Atlanta, Georgia
USA
Voice: (770) 366 6229
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.